COG Phase III Nasopharyngeal Carcinoma

Protocol Title
ARAR0331 Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy

COG
Children’s Oncology Group

Principal Investigator
Joel Kaplan, DO, MPH
joel.kaplan@carolinashealthcare.org

Study Coordinator
Wendy Bissette, RN, BS
wendy.bissette@carolinashealthcare.org

Status
Active

Key Inclusion Criteria*
- Patients must be less than 19 years of age at the time of diagnosis
- Newly diagnosed patients with histological diagnosis of nasopharyngeal carcinoma WHO Type II or III
- Adequate renal and liver function

Key Exclusion Criteria*
- The patient must have received no previous chemotherapy or radiotherapy to the nasopharynx or neck for the treatment of nasopharyngeal carcinoma
- Pregnant or breastfeeding females

Therapies
Chemotherapy
- Amifostine
- 5-Fluorouracil
- Cisplatin

Radiation

Referrals
Please contact for referrals and/or study information:
Wendy Bissette, RN
Ph 704-355-9081
wendy.bissette@carolinashealthcare.org

* Additional criteria apply.  rev. 02/11